Regulatory Risk
Tagged analyses
ETRGulf-coast regulated utility riding a once-in-a-generation industrial load wave at fair price.
Hold · 2026-05-04
SYFCheap private-label card issuer with real moat but cyclical earnings and regulatory overhang.
Buy · 2026-05-05
HCAAmerica's best-run hospital operator, levered to the gills, trading near fair value.
Hold · 2026-05-04
CVSA three-headed conglomerate trading at owner-earnings parity but with no durable moat.
Avoid · 2026-05-03
UBERUber finally earns its keep, but robotaxis make the runway unknowable.
Too Hard · 2026-05-03
UHSA reasonably priced hospital operator with thin moats, founder control, and policy-driven earnings volatility.
Buy · 2026-05-04
GOOGLA wide-moat compounder priced for a war it is also winning.
Buy · 2026-05-03
TSLATesla is too hard: outcome depends on bets we cannot rationally handicap.
Too Hard · 2026-05-03
MSMorgan Stanley is a half-great wealth manager bolted to a cyclical investment bank.
Hold · 2026-05-03
UNHCheap on paper, but regulatory fog and a leadership shock push UNH into the too-hard pile.
Too Hard · 2026-05-03
CNPA leveraged Texas wires monopoly priced for perfection at 1.67x intrinsic value.
Trim · 2026-05-03
EDA fine New York utility at almost twice intrinsic value — pass.
Avoid · 2026-05-04
GSGoldman is a great franchise in a structurally unpredictable business.
Too Hard · 2026-05-03
LLYGreat medicine, fragile math: at $963 we are paying nine times intrinsic value.
Too Hard · 2026-05-03
SATSEchoStar is a spectrum-and-satellite story priced above base intrinsic value.
Too Hard · 2026-05-04
EIXCheap on rate base, but California wildfire risk caps the upside.
Hold · 2026-05-04